Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O15204

UPID:
ADEC1_HUMAN

ALTERNATIVE NAMES:
A disintegrin and metalloproteinase domain-like protein decysin-1

ALTERNATIVE UPACC:
O15204; B7ZAK5

BACKGROUND:
The protein ADAM DEC1, with alternative names such as A disintegrin and metalloproteinase domain-like protein decysin-1, is implicated in crucial biological functions, particularly in controlling the immune response and supporting pregnancy. This protein's role underscores the complexity and importance of immune system modulation and reproductive health.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ADAM DEC1 holds promise for unveiling new therapeutic avenues. Given its significant role in immune modulation and pregnancy, research into ADAM DEC1 could lead to breakthroughs in managing immune disorders and enhancing maternal-fetal health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.